We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info . X close

Cell Therapy Technologies Market: Growth, Size, Share, and Trends

Report Code BT 6823
Published in Dec, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Vessels, Single-Use Equipment), Process (Cell Processing, Preservation, Distribution, QC), Cell type (T-Cells, Stem cells), Application (Cancer, CVD), End user - Global Forecast to 2029

Overview

The global cell therapy technologies market, valued at US$3.89 billion in 2023, is forecasted to grow at a robust CAGR of 11.0%, reaching US$4.03 billion in 2024 and an impressive US$6.80 billion by 2029. The cell therapy technologies market is experiencing robust growth, driven by advancements in regenerative medicine, rising investment in R&D, and the increasing prevalence of chronic and rare diseases. Emerging trends include the integration of AI and machine learning in cell therapy workflows to optimize production and improve outcomes. Additionally, regulatory support and the push for allogeneic therapies—offering scalability and broader accessibility are propelling market expansion. The rapid growth of cell and gene therapy hubs globally, particularly in North America, Europe, and Asia-Pacific, further underscores the market’s potential.

Cell Therapy Technologies Market – Global Forecast and Key Opportunities to 2029

Attractive Opportunities in the Cell Therapy Technologies Market

Asia Pacific

Market growth in the Asia Pacific can be attributed to increasing investments in healthcare infrastructure, R&D by governments and private sectors and region’s large and aging population, coupled with a rising prevalence of chronic and degenerative diseases.

The growing demand for increased funding and investment in cell therapy, and advancements in gene editing technologies, are significantly driving the expansion of the cell therapy technologies market.

Integration with digital technologies such as AI & ML of cell therapy technologies are expected to provide lucrative opportunities for market players.

The Asia Pacific cell therapy technologies market is expected to grow at CAGR of 12.5% during the forecast period.

Stringent and varying halal certification requirements raise challenges to market growth.

Global Cell Therapy Technologies Market Dynamics

DRIVER: Advancements in gene editing technologies

Gene editing technologies, especially CRISPR-Cas9, provide significant growth in the market for cell therapy technologies in terms of making treatments more precise, efficient, and targeted. Tools based on CRISPR and TALEN-based tools improve the accuracy of modifying cells, which are safer and more effective in cell therapies. Efficiency in gene editing shortens the development timeline and enhances clinical outcomes, making it an attractive offering to stakeholders. These innovations enable DNA-level correction of genetic mutations, thereby creating new options for treating genetic disorders as well as increasing the potential efficacy of cell therapies. For example, in March 2021, Caribou Biosciences (US) reported that it has raised USD 115 million in a series C financing round to develop the company's proprietary, next-generation CRISPR technology platform and to advance the company's pipeline of wholly owned allogeneic immune cell therapies for oncology with best-in-class potential. In like manner, Editas Medicine (US) is pushing forward CRISPR-based therapies for inherited retinal blindness and sickle cell disease, further underlining the promise of gene editing.

RESTRAINT: Manufacturing and logistical complexity

Cell therapies, in particular autologous treatments, are characterized by extremely specialized and resource-intensive manufacturing processes that cannot easily be scaled. Autologous treatments involve collecting, engineering, and re-introducing patient-specific cells; standardization and consistency of batch-to-batch remain very challenging. The high standard of Good Manufacturing Practice compliance required for such personalized therapies adds complexity and costs of production.

Logistical and manufacturing complexities greatly impact the scalability, cost, and timely availability of cell therapies. These therapies depend on specialized equipment such as ultra-low temperature freezers costing between USD 10,000–100,000 and liquid nitrogen storage tanks, which are very capital-intensive and carry operational costs like energy consumption and liquid nitrogen refills. There must be strict temperature control on transport because minor temperatures might render the batches unusable. Thus, there would be delays or supplementary manufacturing runs. For example, the CAR-T therapy in KYMRIAH has proven problematic at times, especially when patients have encountered delays due to unusable batches from deviations in transportation or temperature exposure. These are worsened by the absence of cold chain facilities and personnel in less developed regions, which increase the loss risk associated with therapy. The fact that many cell therapies are specific to patients adds more layers of complexity, demanding costly, high-tech, manufacturing facilities with skilled labor-a resource that is rarely found in smaller or decentralized settings. These challenges lead to expensive treatments, delayed commercialization, and restricted access, minimizing the market potential of cell therapies.

 

OPPORTUNITY: Integration with digital technologies such as AI & ML

TERM in the biomedical field is revolutionizing with AI and ML. The integration of tissue engineering and regenerative medicine with AI and ML opens new avenues to optimize cell culture processes, advance organ and tissue engineering, and overcome the major challenges in tissue engineering. These technologies solve the most critical bottlenecks in research, development, and manufacturing and bring about faster timelines and cost-effective solutions for scalable and individualized treatments.

Al algorithms are changing the face of cell line development with the analysis of genomic and phenotypic data for precise genetic modifications. For instance, companies such as Insilico Medicine (US) and Cellarity (US) are applying Al to simulate cellular responses with a significant reduction in trial-and-error experimentation. These could accelerate the development of optimized therapies. For instance, CRISPR-based gene editing uses ML models to predict off-target effects so that gene edits are both accurate and safe. This can improve the development and efficacy of autologous therapies such as CAR-T cells by reducing unintended cellular alteration.

Similarly, Al transforms bioprocessing in manufacturing. Predictive analytics tools track real-time cell growth to identify optimal culture conditions in order to minimize waste and maximize yields.

Companies such as Sartorius (Germany) are also using Al in bioreactors for process control for consistent quality in large-scale production of allogeneic cell therapies. Al also is able to analyze patient-specific data for creating a predictive model on what can be used on a case-to-case basis, in order to optimize success rate and reduce side effects of the drug.

CHALLENGES: Supply chain & cold chain management and manufacturing scalability & quality control

Autologous therapies, like CAR-T, require cryopreservation standards to be as high as -196°C to ensure cell viability through the production and delivery cycle. Temperature control disruption may reduce the efficacy of the product, risking treatment failure and loss of money. For example, Novartis's KYMRIAH relies on the cryogenic logistics systems of companies like Cryoport, which include real-time monitoring and specialized storage solutions. Though they ensure quality, these systems drastically escalate logistics costs; this means financial barriers prevent wide usage. The timeliness of treatments also introduces another logistical complexity: transporting patient-specific cells to and from manufacturing facilities can often delay transport by critical moments. Manufacturing and quality control are major roadblocks in the commercialization of cell therapy technologies due to production processes that are extremely complicated and regulatory requirements very high. Autologous therapies, such as CAR-T, are manufactured per patient and are resource demanding with the possibility of high batch variability.All of the lots must strictly follow Good Manufacturing Practice, where even minor deviations sometimes might lead to contamination, potency loss, or delay.

Global Cell Therapy Technologies Market Ecosystem Analysis

The cell therapy technologies market operates within a complex ecosystem with a wide array of stakeholders, each playing a crucial role in developing and adopting cell therapy technologies. This ecosystem encompasses manufacturers, suppliers, end users, and regulatory bodies. It evaluates their interactions, dependencies, and contributions within the industry, providing insights into the broader market dynamics and trends. Prominent companies in the market include companies operating for several years that possess diversified product portfolios, strong global sales, and marketing networks.

Cell Therapy Technologies Market Ecosystem
 

Media, sera & reagents segment dominated the cell therapy technologies market in 2023.

The product segment is segmented media, sera & reagents, cell engineering products, cell culture vessels, cell therapy equipment, systems & software, and other products. The media, sera & reagents cell therapy technologies segment dominated product segments owing to various factors such as increasing adoption of gene therapies and cell therapies across pharmaceutical and biotech research. The cell engineering segment is anticipated to grow at a significant CAGR owing to Increasing investments by companies to develop advanced products. Factors such as growing demand for advanced cell therapy technologies in cell therapy and gene-editing application driving the growth of segment. Increasing adoption of cell-based therapies, including CAR-T cell therapies, alongside innovations in viral delivery systems further accelerating market growth.

Cell Processing segment dominated the cell therapy technologies market in 2023.

Cell therapy technologies market is segmented by process into cell processing, cell preservation, cell distribution, cell handling, and process monitoring & quality control. The cell processing is further categorized into cell collection, cell isolation, cell expansion, and cell characterization. The cell processing segment dominated the market in 2023. The segment's dominance is attributable to its fundamental role in the development and manufacturing of cell-based therapies. The increasing demand for individualized treatments, such as CAR-T and stem cell therapies, further increases the need for effective, scalable cell processing solutions. Increasing automation, GMP compliant systems, and more optimized protocols are driving this segment's growth further.

T-cells segment dominated the cell therapy technologies market in 2023.

The market is divided into T-cells, stem cells, and other cells based on type. T cells dominated the market in 2023. The main drivers for the growth of the in vivo segment include the rising incidence of diseases such as cancer, increased government investment in cell-based therapies, and increasing demand for T-cell therapies, which significantly support the growth of the segment.

Cardiovascular diseases segment grows at a significant CAGR in cell therapy technologies market in 2023.

The application segment is segmented into cancer, cardiovascular disease (CVD), orthopedic disorders, autoimmune diseases, and other applications. The cardiovascular disease application segment application segment holds significant CAGR in 2023. Growing prevalence of heart diseases and the unmet need for regenerative treatment options drives the growth of segment. Advancements in stem cell research, high R&D investment, and strategic collaborations in this area would drive innovation for the overall market. This, added to supportive regulatory frameworks and scalable manufacturing solutions for commercializing the CVD segment, enhances the potential and positioning this segment as the most growth-driving area for the overall market.

The end user segment is likely to grow at a significant CAGR from 2024 to 2029.

The end-user market is categorized into the biopharmaceutical & biotechnology companies, CROs & CMOs, research institutes, and cell banks. The biopharmaceutical & biotechnology companies dominated the segment in 2023; the CROs & CMOs are likely to grow at a significant CAGR. The demand for outsourced services is growing in the development and manufacturing of cell therapy. Given the focus on core activities, biopharma companies are increasingly reliant on CROs and CMOs for specialized expertise, cost-effective solutions, and scalable operations. The ever-increasing number of clinical trials and commercialization of cell therapies amplify the need for outsourced support, which places this segment at the ready for significant growth in the market.

North America was the largest regional market for cell therapy technologies in 2023.

Based on region, the cell therapy technologies market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America dominated the global cell therapy technologies market. It is anticipated to maintain dominance during the forecast period. The Asia Pacific cell therapy technologies market is anticipated to grow at a significant CAGR during the forecast period. The increasing number of collaborations between local and global biotech firms is likely to surge the market growth in the region. Furthermore, increasing investment in healthcare infrastructure and adoption of AI and big data in healthcare in Asia Pacifc countries, propelling the demand and driving market growth.

HIGHEST CAGR MARKET IN 2024
NORTH AMERICA FASTEST GROWING MARKET IN THE REGION
Cell Therapy Technologies Market Region

Recent Developments of Cell Therapy Technologies Market

  • In September 2024, Lonza and Vertex entered a commercial supply agreement for CASGEVY, the world’s first CRISPR/Cas9 gene-edited cell therapy.
  • In August 2024, Merck acquired Mirus Bio to advance Merck's integrated offering for viral vector manufacturing
  • In June 2024, Thermo Fisher launched the Thermo Scientific Heracell VIOS 250i AxD CO2 Incubators to deliver new features compatible with lab automation, supporting emerging automated cell therapy production processes.
  • In April 2024, Cytiva launched three new cell lines under the ELEVECTA brand to meet the challenges and increasing demand of viral vector manufacturing.

Key Market Players

Want to explore hidden markets that can drive new revenue in Cell Therapy Technologies Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Value (USD)
Segments covered Product, Process, Cell Type, Application and End User
Geographies covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

 

Key Questions Addressed by the Report

Who are the key players in the cell therapy technologies market?
Key players in the cell therapy technologies market include Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany).
Which product segment dominates the cell therapy technologies market?
The market, by product, is segmented as media, sera & reagents, cell engineering products, cell culture vessels, cell therapy equipment, systems & software, and other products. The media, sera & reagents segment dominated the market in 2023.
Which process segment dominates the cell therapy technologies market?
The market, by process, is segmented as cell processing, cell preservation, cell distribution, cell handling, and process monitoring & quality control. The cell processing segment dominated the market in 2023.
Which cell type segment dominates the cell therapy technologies market?
The market, by cell type, is segmented as T-cells, stem cells and other cells. The T-cells segment dominated the market in 2023
Which application segment dominates the cell therapy technologies market?
The market, by application, is segmented as cancer, cardiovascular disease (CVD), orthopedic disorders, autoimmune diseases, and other applications. The cancer application segment dominated the market in 2023.
Which end-user segment of the cell therapy technologies market is expected to register the highest growth?
The biopharmaceutical & biotechnology companies segment is anticipated to register the highest CAGR during the forecast period.
What is the market size for the cell therapy technologies market?
The global cell therapy technologies market is anticipated to reach USD 6.80 billion in 2029 from USD 4.03 billion in 2024, with a significant CAGR of 11.0%.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Cell Therapy Technologies Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
38
RESEARCH METHODOLOGY
43
EXECUTIVE SUMMARY
56
PREMIUM INSIGHTS
61
MARKET OVERVIEW
64
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increased funding and investment in cell therapy
    - Advancements in gene editing technologies
    - Development of automated cell processing systems
    - Regulatory support for fast-tracking therapies
    RESTRAINTS
    - Manufacturing and logistical complexity
    OPPORTUNITIES
    - Personalized and off-the-shelf cell therapies
    - Integration with digital technologies such as AI & ML
    CHALLENGES
    - Supply chain & cold chain management and manufacturing scalability & quality control
  • 5.3 ECOSYSTEM ANALYSIS
    PRODUCT PROVIDERS
    END USERS
    REGULATORY BODIES
  • 5.4 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Magnetic-activated cell sorting
    - Cryopreservation
    - Gene editing technologies
    - Bioprocessing technologies
    COMPLEMENTARY TECHNOLOGIES
    - Artificial intelligence and machine learning
    - Biomaterials and scaffolding
    - Automation and scalability
    ADJACENT TECHNOLOGIES
    - Nanotechnology
    - Immunotherapy platforms
  • 5.5 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY KEY PLAYER, 2022–2024
    AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT, BY REGION, 2022–2024
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 PATENT ANALYSIS
  • 5.8 TRADE ANALYSIS
    IMPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS, OR ELECTROPHORESIS (HS CODE: 854330)
    EXPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS, OR ELECTROPHORESIS (HS CODE: 854330)
  • 5.9 KEY CONFERENCES AND EVENTS, 2025–2026
  • 5.10 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY FRAMEWORK
    - North America
    - Europe
    - Asia Pacific
    - Rest of the World
  • 5.11 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF BUYERS
    BARGAINING POWER OF SUPPLIERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS
    BUYING CRITERIA
  • 5.13 INVESTMENT & FUNDING SCENARIO
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES
  • 5.15 IMPACT OF AI/GEN AI ON CELL THERAPY TECHNOLOGIES MARKET
CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT
98
  • 6.1 INTRODUCTION
  • 6.2 MEDIA, SERA, AND REAGENTS
    IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING TO DRIVE MARKET
  • 6.3 CELL THERAPY EQUIPMENT
    CELL PROCESSING EQUIPMENT
    - Development of automated and closed-system cell processing equipment to accelerate segment growth
    SINGLE-USE EQUIPMENT
    - Increasing funding for stem cell therapy to drive market
    OTHER CELL THERAPY EQUIPMENT
  • 6.4 SYSTEMS & SOFTWARE
    RISING DEMAND FOR CELL THERAPIES TO SUPPORT MARKET GROWTH
  • 6.5 CELL CULTURE VESSELS
    RISING R&D AND INVESTMENTS IN CELL-BASED THERAPIES TO DRIVE DEMAND
  • 6.6 CELL ENGINEERING PRODUCTS
    AVAILABILITY OF WIDE RANGE OF CELL ENGINEERING PRODUCTS TO SUPPORT MARKET
  • 6.7 OTHER PRODUCTS
CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS
130
  • 7.1 INTRODUCTION
  • 7.2 CELL PROCESSING
    CELL EXPANSION
    - Rising demand for personalized and regenerative therapies to drive market growth
    CELL ISOLATION
    - Rising need for scalable, efficient isolation technologies to drive market
    CELL CHARACTERIZATION
    - Increasing demand for high-quality, safe, and effective cell-based therapies to propel growth
    CELL COLLECTION
    - Advancements in cell collection technologies to drive market
  • 7.3 CELL PRESERVATION
    ADVANCEMENT IN CRYOPRESERVATION TECHNOLOGIES TO DRIVE GROWTH
  • 7.4 PROCESS MONITORING & QUALITY CONTROL
    INCREASING DEMAND FOR AUTOMATED QUALITY CONTROL IN CELL THERAPY PRODUCTION TO DRIVE MARKET
  • 7.5 CELL HANDLING
    INCREASING DEMAND FOR AUTOMATED, EFFICIENT, AND SCALABLE SOLUTIONS TO DRIVE MARKET GROWTH
  • 7.6 CELL DISTRIBUTION
    INCREASED FOCUS ON TRANSPORTATION AND STORAGE TO DRIVE MARKET GROWTH
CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE
163
  • 8.1 INTRODUCTION
  • 8.2 T CELLS
    RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE GROWTH
  • 8.3 STEM CELLS
    INCREASING FUNDING FOR STEM CELL RESEARCH TO PROPEL MARKET
  • 8.4 OTHER CELLS
CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION
176
  • 9.1 INTRODUCTION
  • 9.2 CANCER
    RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE SEGMENT GROWTH
  • 9.3 CARDIOVASCULAR DISEASE
    INCREASING FOCUS ON INNOVATIVE CELL THERAPY APPROACHES TO DRIVE MARKET
  • 9.4 ORTHOPEDIC DISORDERS
    INCREASING FOCUS ON STEM CELL THERAPY FOR TISSUE REGENERATION TO DRIVE MARKET
  • 9.5 AUTOIMMUNE DISEASES
    INCREASING FUNDING FOR STEM CELL RESEARCH TO SUPPORT MARKET GROWTH
  • 9.6 OTHER APPLICATIONS
    CELL THERAPY TECHNOLOGIES MARKET, BY END USER
CELL THERAPY TECHNOLOGIES MARKET, BY END USER
196
  • 10.1 INTRODUCTION
  • 10.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    INCREASING ADOPTION OF INORGANIC GROWTH STRATEGIES BY BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
  • 10.3 CROS & CMOS
    FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH
  • 10.4 RESEARCH INSTITUTES
    RISING RESEARCH ACTIVITY TO SUPPORT MARKET GROWTH
  • 10.5 CELL BANKS
    INCREASING DEMAND FOR STANDARDIZED CELL LINES TO SUPPORT MARKET GROWTH
CELL THERAPY TECHNOLOGIES MARKET, BY REGION
213
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - US dominates North American cell therapy technologies market
    CANADA
    - Increasing government funding to drive adoption of cell therapy instruments
  • 11.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Germany to hold largest market share
    UK
    - Favorable funding & investment scenario to drive market growth
    FRANCE
    - Availability of government & private funding to support market growth
    ITALY
    - Increasing R&D, public & private investment, and support to offer growth opportunities
    SPAIN
    - Advancement in personalized medicine to stimulate market
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Increasing R&D expenditure to drive market growth
    JAPAN
    - Strong availability of funding to support market growth
    INDIA
    - Rising funding programs to drive market
    AUSTRALIA
    - Increasing government funding & initiatives to drive market growth
    SOUTH KOREA
    - Alliances & investments in research to drive market
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Brazil to dominate Latin American market till 2029
    MEXICO
    - Strong pharmaceutical industry and increased government support to augment market
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    GCC COUNTRIES
    - Saudi Arabia
    - UAE
    - Rest of GCC Countries
    REST OF MIDDLE EAST
  • 11.7 AFRICA
    MACROECONOMIC OUTLOOK FOR AFRICA
COMPETITIVE LANDSCAPE
329
  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET
  • 12.3 REVENUE ANALYSIS
  • 12.4 MARKET SHARE ANALYSIS
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Region footprint
    - Product footprint
    - Process footprint
    - Cell type footprint
    - Application footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 12.8 BRAND/PRODUCT COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES
    DEALS
    EXPANSIONS
COMPANY PROFILES
350
  • 13.1 KEY PLAYERS
    DANAHER CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    MERCK KGAA
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    LONZA
    - Business overview
    - Products offered
    - Recent developments
    SARTORIUS AG
    - Business overview
    - Products offered
    - Recent developments
    AGILENT TECHNOLOGIES, INC.
    - Business overview
    - Products offered
    - Recent developments
    AVANTOR, INC.
    - Business overview
    - Products offered
    - Recent developments
    FRESENIUS SE & CO. KGAA
    - Business overview
    - Products offered
    - Recent developments
    BECTON, DICKINSON AND COMPANY
    - Business overview
    - Products offered
    - Recent developments
    CORNING INCORPORATED
    - Business overview
    - Products offered
    TERUMO CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    BIO-TECHNE
    - Business overview
    - Products offered
    - Recent developments
    GENSCRIPT
    - Business overview
    - Products offered
    - Recent developments
    MAXCYTE
    - Business overview
    - Products offered
    - Recent developments
    STEMCELL TECHNOLOGIES
    - Business overview
    - Products offered
    - Recent developments
  • 13.2 OTHER PLAYERS
    OXFORD BIOMEDICA PLC
    ROOSTERBIO, INC.
    TRAKCEL
    L7 INFORMATICS, INC.
    MILTENYI BIOTEC
    REPLIGEN CORPORATION
    MAK SYSTEM
    ORIGEN BIOMEDICAL, INC.
    IXCELLS BIOTECHNOLOGIES
    KÖRBER AG
APPENDIX
458
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 2 CELL THERAPY TECHNOLOGIES MARKET: RISK ANALYSIS
  • TABLE 3 CELL THERAPY TECHNOLOGIES MARKET: KEY PRODUCT PROVIDERS
  • TABLE 4 CELL THERAPY TECHNOLOGIES MARKET: KEY END USERS
  • TABLE 5 CELL THERAPY TECHNOLOGIES MARKET: REGULATORY BODIES
  • TABLE 6 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS, BY KEY PLAYER, 2022–2024
  • TABLE 7 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT, BY REGION, 2022–2024
  • TABLE 8 KEY PATENTS IN CELL THERAPY TECHNOLOGIES MARKET, 2021–2024
  • TABLE 9 IMPORT VOLUME FOR HS CODE 854330, 2019–2023 (UNITS)
  • TABLE 10 EXPORT VOLUME FOR HS CODE 854330, 2019–2023 (UNITS)
  • TABLE 11 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 CELL THERAPY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP FOUR END USERS
  • TABLE 18 KEY BUYING CRITERIA FOR CELL THERAPY TECHNOLOGIES PRODUCTS, BY END USER
  • TABLE 19 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 20 CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 21 NORTH AMERICA: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 22 EUROPE: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 23 ASIA PACIFIC: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 24 LATIN AMERICA: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 25 MIDDLE EAST: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 26 GCC COUNTRIES: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 27 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 28 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 29 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 30 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 31 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 32 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 33 MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 34 GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 35 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 36 NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 37 EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 38 ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 39 LATIN AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 40 MIDDLE EAST: CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 41 GCC COUNTRIES: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 42 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 43 NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 44 EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 46 LATIN AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 47 MIDDLE EAST: SINGLE-USE EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 48 GCC COUNTRIES: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 49 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 50 NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 52 ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 53 LATIN AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 54 MIDDLE EAST: OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 55 GCC COUNTRIES: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 56 CELL THERAPY SYSTEMS & SOFTWARE, BY COMPANY
  • TABLE 57 CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 58 NORTH AMERICA: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 59 EUROPE: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 60 ASIA PACIFIC: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 61 LATIN AMERICA: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 62 MIDDLE EAST: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 63 GCC COUNTRIES: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 64 CELL CULTURE VESSELS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 65 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 66 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 68 LATIN AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 69 MIDDLE EAST: CELL CULTURE VESSELS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 70 GCC COUNTRIES: CELL CULTURE VESSELS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 71 CELL ENGINEERING PRODUCTS OFFERED, BY COMPANY
  • TABLE 72 CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 73 NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 74 EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 75 ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 76 LATIN AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 77 MIDDLE EAST: CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 78 GCC COUNTRIES: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 79 OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 80 NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 81 EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 82 ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 83 LATIN AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 84 MIDDLE EAST: OTHER CELL THERAPY PRODUCTS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 85 GCC COUNTRIES: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 86 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 87 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 88 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 89 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 90 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 91 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 92 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 93 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 94 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 95 CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 96 CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 97 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 99 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 100 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 101 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 102 CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 103 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 104 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 106 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 107 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 108 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 109 CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 110 CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 111 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 113 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 114 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 115 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 116 CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 117 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 118 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 120 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 121 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 122 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 123 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 124 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 125 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 126 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 127 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 128 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 129 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 130 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 131 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 132 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 133 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 134 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 135 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 136 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 137 CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 138 CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 139 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 140 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 141 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 142 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 143 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 144 CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 145 CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 146 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 147 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 148 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 149 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 150 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 151 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 152 T-CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 153 NORTH AMERICA: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 154 EUROPE: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 156 LATIN AMERICA: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 157 MIDDLE EAST: T-CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 158 GCC COUNTRIES: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 159 STEM CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 160 NORTH AMERICA: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 161 EUROPE: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 162 ASIA PACIFIC: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 163 LATIN AMERICA: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 164 MIDDLE EAST: STEM CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 165 GCC COUNTRIES: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 166 OTHER CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 167 NORTH AMERICA: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 168 EUROPE: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 169 ASIA PACIFIC: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 170 LATIN AMERICA: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 171 MIDDLE EAST: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 172 GCC COUNTRIES: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 173 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 174 CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 175 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 176 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 177 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 178 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 179 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 180 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 181 CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 182 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 183 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 184 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 185 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 186 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 187 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 188 CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 189 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 190 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 191 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 192 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 193 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 194 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 195 CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 196 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 197 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 198 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 199 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 200 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 201 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 202 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 203 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 204 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 205 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 206 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 207 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 208 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 209 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 210 CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 211 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 212 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 213 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 214 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 215 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 216 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 217 CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 218 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 219 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 220 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 221 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 222 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 223 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 224 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 225 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 226 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 228 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 229 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 230 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 231 CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 232 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 233 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 234 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 235 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 236 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 237 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 238 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 239 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 240 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 241 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 242 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 243 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 244 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 245 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 246 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 247 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 248 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 249 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 250 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 251 US: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 252 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 253 US: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 254 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 255 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 256 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 257 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 258 CANADA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 259 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 260 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 261 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 262 EUROPE: KEY MACROINDICATORS
  • TABLE 263 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 264 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 265 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 266 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 267 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 268 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 269 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 270 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 271 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 272 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 273 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 274 GERMANY: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 275 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 276 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 277 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 278 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 279 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 280 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 281 UK: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 282 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 283 UK: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 284 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 285 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 286 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 287 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 288 FRANCE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 289 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 290 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 291 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 292 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 293 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 294 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 295 ITALY: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 296 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 297 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 298 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 299 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 300 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 301 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 302 SPAIN: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 303 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 304 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 305 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 306 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 307 REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 308 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 309 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 310 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 311 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 312 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 313 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 314 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 315 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 316 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 317 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 318 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 319 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 320 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 321 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 322 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 323 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 324 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 325 CHINA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 326 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 327 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 328 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 329 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 330 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 331 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 332 JAPAN: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 333 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 334 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 335 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 336 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 337 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 338 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 339 INDIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 340 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 341 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 342 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 343 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 344 AUSTRALIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 345 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 346 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 347 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 348 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 349 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 350 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 351 SOUTH KOREA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 352 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 353 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 354 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 355 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 356 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 357 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 358 REST OF ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 359 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 360 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 361 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 362 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 363 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 364 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 365 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 366 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 367 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 368 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 369 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 370 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 371 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 372 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 373 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 374 BRAZIL: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 375 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 376 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 377 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 378 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 379 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 380 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 381 MEXICO: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 382 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 383 MEXICO: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 384 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 385 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 386 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 387 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 388 REST OF LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 389 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 390 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 391 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 392 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 393 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 394 MIDDLE EAST: KEY MACROINDICATORS
  • TABLE 395 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 396 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 397 MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 398 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 399 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 400 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 401 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 402 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 403 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 404 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 405 GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 406 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 407 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 408 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 409 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 410 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 411 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 412 SAUDI ARABIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 413 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 414 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 415 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 416 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 417 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 418 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 419 UAE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 420 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 421 UAE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 422 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 423 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 424 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 425 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 426 REST OF GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 427 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 428 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 429 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 430 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 431 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 432 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 433 REST OF MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 434 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 435 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 436 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 437 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 438 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 439 AFRICA: KEY MACROINDICATORS
  • TABLE 440 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
  • TABLE 441 AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 442 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION)
  • TABLE 443 AFRICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 444 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION)
  • TABLE 445 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 446 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 447 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES, 2021–2023
  • TABLE 448 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION
  • TABLE 449 CELL THERAPY TECHNOLOGIES MARKET: REGION FOOTPRINT
  • TABLE 450 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT FOOTPRINT
  • TABLE 451 CELL THERAPY TECHNOLOGIES MARKET: PROCESS FOOTPRINT
  • TABLE 452 CELL THERAPY TECHNOLOGIES MARKET: CELL TYPE FOOTPRINT
  • TABLE 453 CELL THERAPY TECHNOLOGIES MARKET: APPLICATION FOOTPRINT
  • TABLE 454 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 455 CELL THERAPY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • TABLE 456 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT LAUNCHES, JANUARY 2021–NOVEMBER 2024
  • TABLE 457 CELL THERAPY TECHNOLOGIES MARKET: DEALS, JANUARY 2021– NOVEMBER 2024
  • TABLE 458 CELL THERAPY TECHNOLOGIES MARKET: EXPANSIONS, JANUARY 2021– NOVEMBER 2024
  • TABLE 459 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 460 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 461 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2021– OCTOBER 2024
  • TABLE 462 DANAHER CORPORATION: DEALS, JANUARY 2021– OCTOBER 2024
  • TABLE 463 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021– OCTOBER 2024
  • TABLE 464 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 465 MERCK KGAA: PRODUCTS OFFERED
  • TABLE 466 MERCK KGAA: DEALS, JANUARY 2021–SEPTEMBER 2024
  • TABLE 467 MERCK KGAA: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024
  • TABLE 468 THERMO FISHER SCIENTIFIC INC: COMPANY OVERVIEW
  • TABLE 469 THERMO FISHER SCIENTIFIC INC: PRODUCTS OFFERED
  • TABLE 470 THERMO FISHER SCIENTIFIC INC: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024
  • TABLE 471 THERMO FISHER SCIENTIFIC INC: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 472 THERMO FISHER SCIENTIFIC INC: EXPANSIONS, JANUARY 2021–OCTOBER 2024
  • TABLE 473 LONZA: COMPANY OVERVIEW
  • TABLE 474 LONZA: PRODUCTS OFFERED
  • TABLE 475 LONZA: PRODUCT LAUNCHES, JANUARY 2021– OCTOBER 2024
  • TABLE 476 LONZA: DEALS, JANUARY 2021– OCTOBER 2024
  • TABLE 477 SARTORIUS: COMPANY OVERVIEW
  • TABLE 478 SARTORIUS AG: PRODUCTS OFFERED
  • TABLE 479 SARTORIUS AG: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 480 SARTORIUS AG: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 481 SARTORIUS AG: EXPANSIONS, JANUARY 2021– OCTOBER 2024
  • TABLE 482 AGILENT TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 483 AGILENT TECHNOLOGIES: PRODUCTS OFFERED
  • TABLE 484 AGILENT TECHNOLOGIES: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 485 AGILENT TECHNOLOGIES: DEALS, JANUARY 2021– OCTOBER 2024
  • TABLE 486 AVANTOR: COMPANY OVERVIEW
  • TABLE 487 AVANTOR: PRODUCTS OFFERED
  • TABLE 488 AVANTOR: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 489 FRESENIUS: COMPANY OVERVIEW
  • TABLE 490 FRESENIUS: PRODUCTS OFFERED
  • TABLE 491 FRESENIUS: DEALS, JANUARY 2021–SEPTEMBER 2024
  • TABLE 492 BD: COMPANY OVERVIEW
  • TABLE 493 BD: PRODUCTS OFFERED
  • TABLE 494 BD: PRODUCT LAUNCHES, JANUARY 2021– OCTOBER 2024
  • TABLE 495 CORNING INCORPORATED: COMPANY OVERVIEW
  • TABLE 496 CORNING INCORPORATED: PRODUCTS OFFERED
  • TABLE 497 TERUMO CORPORATION: COMPANY OVERVIEW
  • TABLE 498 TERUMO CORPORATION: PRODUCTS OFFERED
  • TABLE 499 TERUMO CORPORATION: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 500 TERUMO CORPORATION: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 501 TERUMO CORPORATION: EXPANSIONS, JANUARY 2021–OCTOBER 2024
  • TABLE 502 BIO-TECHNE: COMPANY OVERVIEW
  • TABLE 503 BIO-TECHNE: PRODUCTS OFFERED
  • TABLE 504 BIO-TECHNE: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024
  • TABLE 505 BIO-TECHNE: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 506 BIO-TECHNE: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024
  • TABLE 507 GENSCRIPT: COMPANY OVERVIEW
  • TABLE 508 GENSCRIPT: PRODUCTS OFFERED
  • TABLE 509 GENSCRIPT: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 510 MAXCYTE: COMPANY OVERVIEW
  • TABLE 511 MAXCYTE: PRODUCTS OFFERED
  • TABLE 512 MAXCYTE: DEALS, JANUARY 2021–OCTOBER 2024
  • TABLE 513 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 514 STEMCELL TECHNOLOGIES: PRODUCTS OFFERED
  • TABLE 515 STEMCELL TECHNOLOGIES: PRODUCT LAUNCHES, JANUARY 2021– OCTOBER 2024
  • TABLE 516 STEMCELL TECHNOLOGIES: DEALS, JANUARY 2021–OCTOBER 2024
LIST OF FIGURES
 
  • FIGURE 1 CELL THERAPY TECHNOLOGIES MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 CELL THERAPY TECHNOLOGIES MARKET: RESEARCH DESIGN
  • FIGURE 3 CELL THERAPY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 4 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
  • FIGURE 5 MARKET SIZE ESTIMATION APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION: REVENUE SHARE ANALYSIS (2023)
  • FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 9 CELL THERAPY TECHNOLOGIES MARKET: CAGR PROJECTIONS
  • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CELL THERAPY TECHNOLOGIES MARKET (2024-2029)
  • FIGURE 17 INCREASED FUNDING & INVESTMENT IN CELL THERAPY AND ADVANCEMENTS IN GENE EDITING TECHNOLOGIES TO DRIVE MARKET
  • FIGURE 18 US ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 19 MEDIA, SERA, AND REAGENTS TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 20 APAC COUNTRIES TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 21 CELL THERAPY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 CELL THERAPY TECHNOLOGIES MARKET: ECOSYSTEM
  • FIGURE 23 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT, 2024 (USD THOUSAND)
  • FIGURE 24 CELL THERAPY TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 25 CELL THERAPY TECHNOLOGIES MARKET: OVERVIEW OF PATENTING ACTIVITY
  • FIGURE 26 CELL THERAPY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
  • FIGURE 28 KEY BUYING CRITERIA FOR TOP FOUR END USERS
  • FIGURE 29 GOVERNMENT FUNDING FOR R&D FROM 2019–2024
  • FIGURE 30 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 31 CELL THERAPY TECHNOLOGIES MARKET: IMPACT OF AI
  • FIGURE 32 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
  • FIGURE 33 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT
  • FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET, 2021–2023
  • FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET, 2023
  • FIGURE 36 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 37 CELL THERAPY TECHNOLOGIES MARKET: COMPANY FOOTPRINT
  • FIGURE 38 CELL THERAPY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 39 EV/EBITDA OF KEY VENDORS
  • FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 41 CELL THERAPY TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT
  • FIGURE 44 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT
  • FIGURE 45 LONZA: COMPANY SNAPSHOT
  • FIGURE 46 SARTORIUS AG: COMPANY SNAPSHOT
  • FIGURE 47 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
  • FIGURE 48 AVANTOR: COMPANY SNAPSHOT
  • FIGURE 49 FRESENIUS: COMPANY SNAPSHOT
  • FIGURE 50 BD: COMPANY SNAPSHOT
  • FIGURE 51 CORNING INCORPORATED: COMPANY SNAPSHOT
  • FIGURE 52 TERUMO CORPORATION: COMPANY SNAPSHOT
  • FIGURE 53 BIO-TECHNE: COMPANY SNAPSHOT
  • FIGURE 54 GENSCRIPT: COMPANY SNAPSHOT
  • FIGURE 55 MAXCYTE: COMPANY SNAPSHOT

 

The research study involved the wide use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global cell therapy technologies market. Extensive interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size estimated through secondary research (top down and bottom-up) followed by data triangulation with inputs from industry experts to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the technical, market-oriented, and commercial study of the cell therapy technologies market. The secondary sources used for this study include FDA (US Food and Drug Administration), EMA (European Medicines Agency), NIH (National Institutes of Health), ClinicalTrials.gov, PMDA (Pharmaceuticals and Medical Devices Agency, Japan), Horizon Europe (EU Research and Innovation Program), MHRA (Medicines and Healthcare products Regulatory Agency, UK), European Society of Gene and Cell Therapy (ESGCT), California Institute for Regenerative Medicine (CIRM) World Health Organization (WHO), International Society for Cell & Gene Therapy (ISCT), CBER (Center for Biologics Evaluation and Research), NIH Regenerative Medicine Program, National Medical Products Administration (NMPA), China, Health Canada – Biologics and Genetic Therapies Directorate (BGTD) Eurostat, Factiva, and GLOBOCAN, ScienceDirect, Eurostat, research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These secondary sources were also used to obtain major information about key market players, and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analyzed to arrive at the market size of the global cell therapy technologies market, which was further validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global cell therapy technologies market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as biopharmaceutical & biotechnology companies, CROs and CMOs, research institutes and cell banks from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. The primary interviews were conducted across six major regions, including North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

Cell Therapy Technologies Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell therapy technologies market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

The market size estimations includes the following:

Cell Therapy Technologies Market

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Cell therapy is a transformative area that represents a groundbreaking advancement in modern medicine, leveraging living cells to repair, replace, or regenerate damaged tissues and treat a wide range of diseases. This innovative approach involves introducing functional cells into a patient’s body to restore health, offering solutions for conditions that were once considered untreatable. With applications spanning autologous therapies, which utilize a patient’s cells, and allogeneic therapies, offering scalable off-the-shelf solutions, cell therapy is transforming healthcare delivery.

Stakeholders

  • Cell therapy product manufacturers, suppliers, and processors
  • Distributors and suppliers of cell therapy products
  • Biotechnology and biopharmaceutical companies
  • Contract manufacturing organizations (CMOs)
  • Suppliers and distributors of pharmaceutical products
  • Research and development (R&D) companies
  • Pharmaceutical/medical associations
  • Trade associations and industry bodies
  • Regulatory bodies and government agencies
  • Research institutes and government organizations
  • Venture capitalists and investors
  • Business research and consulting service providers
  • Market research and consulting firms

Report Objectives

  • To define, describe, and forecast the cell therapy technologies market based on product, process, cell type, application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall cell therapy technologies market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the market size of the segments in six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa
  • To profile the key players and analyze their market shares and core competencies2
  • To track and analyze competitive developments, such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategies
  • To study trends & disruptions impacting business; apply pricing analysis, supply/value chain analysis, ecosystem analysis, technology analysis, patent analysis, and trade analysis; and identify key conferences & events in 2025–2026, key stakeholders & buying criteria, and the investment & funding scenario
  • To study the impact of AI/Gen AI on the market under study, along with the macroeconomic outlook for each region.

Previous Versions of this Report

Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single Use Equipment, Systems & Software), Process (Cell Processing), Cell Type (T-cells, Stem Cells), End User (Biopharma, CMOs), Region - Global Forecast to 2027

Report Code BT 6823
Published in Jul, 2023, By MarketsandMarkets™

Cell Therapy Technologies Market by Product (Media, Sera & Reagents, Cell Culture Vessels, Single Use Equipment, Systems & Software), Process (Cell Processing), Cell Type (T-cells, Stem Cells), End User (Biopharma, CMOs), Region - Global Forecast to 2027

Report Code BT 6823
Published in Aug, 2022, By MarketsandMarkets™

Cell Therapy Technologies Market by Product (Consumables, Equipment (Single-Use Equipment, Other Equipment), Systems & Software), Process (Cell Processing), Cell Type (T-cells, Stem Cells), End User (Research Institutes) - Global Forecast to 2025

Report Code BT 6823
Published in Oct, 2020, By MarketsandMarkets™

Cell Therapy Technologies Market by Product (Consumables, Equipment (Single-Use Equipment, Other Equipment), Systems & Software), Process (Cell Processing), Cell Type (T-cells, Stem Cells), End User (Research Institutes) - Global Forecast to 2025

Report Code BT 6823
Published in Dec, 2018, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

https://www.mnmks.com/demointeractivereports/display/NWI1MTkzNDQxZjZmNTUxYTlkYjFkZWE1Zjg0ODk1NjBiZWQxYmNmZDA4MjBhNTU3OTExNzg0ZWJmNDk2ZDdjY50hkOYTk7MlqWh0z9CFErEgjXCnc_V4HFrQsjRd94bBJkyv0xSPA3H7RvJv5S2cFQ,,/0/Home%20Page%20-%20Search%20view%20-%20Markets%20-%20CELL%20THERAPY

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Cell Therapy Technologies Market

DMCA.com Protection Status